Sugi Predict

Sugi Predict / Compounds / SCHEMBL578360

SCHEMBL578360

SCHEMBL578360

COc1ccc2c(c1)CC(=O)N2Cc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ APAF1 O14727 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ CASP3 P42574 1/20 0.57
▸ SENP8 Q96LD8 1/20 0.57
▸ SENP7 Q9BQF6 1/20 0.57
▸ SENP6 Q9GZR1 1/20 0.57
▸ MDH2 P40926 1/20 0.55
▸ PTGDR2 Q9Y5Y4 1/20 0.51
▸ PARK7 Q99497 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPT P10636 3/20 0.49
▸ HPGD P15428 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.48
▸ CMA1 P23946 1/20 0.48
▸ GSK3B P49841 1/20 0.47
▸ ACHE P22303 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30068092 1.00 MEN1 (0.57) MEN1KMT2AAPAF1GAACASP3
SCHEMBL9097217 0.86 DRD2 (0.58) MEN1KMT2AALDH1A1ACHEBACE1
SCHEMBL14938439 0.83 MEN1 (0.71) MEN1KMT2AAPAF1GAACASP3
SCHEMBL578266 0.82 KMT2A (0.62) MEN1KMT2AAPAF1MDH2POLB
SCHEMBL3020306 0.82 MEN1 (0.55) MEN1KMT2AAPAF1GAACASP3
SCHEMBL9096175 0.81 ACHE (0.67) ACHEBACE1
SCHEMBL26646898 0.81 BRD4 (0.56) MEN1KMT2AAPAF1GAACASP3
SCHEMBL30489293 0.80 MEN1 (0.48) MEN1KMT2APTGDR2PARK7L3MBTL1
SCHEMBL28995167 0.80 MEN1 (0.48) MEN1KMT2APTGDR2PARK7L3MBTL1
SCHEMBL29173745 0.80 CMA1 (0.54) MEN1KMT2AAPAF1GAACASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS INC (US) 2026-04-23 — — US disclosed
US-12312339-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2025-05-27 — — US disclosed
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-08-15 — — US disclosed
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2024-04-18 — — US disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 — — WO disclosed
WO-2024076891-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. (US) 2024-04-11 — — WO disclosed
CN-117794529-A POLO-like kinase 4 inhibitors 欧瑞克制药公司 2024-03-29 — — CN disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-11858915-B2 Polo like kinase 4 inhibitors ORIC PHARMACEUTICALS, INC. (US) 2024-01-02 — — US disclosed
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS ORIC PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20110263598-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER UNIVERSITY HEALTH NETWORKS (CA) 2011-10-27 — — US disclosed
US-20110263598-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER UNIVERSITY HEALTH NETWORKS (CA) 2011-10-27 — — US disclosed
US-20110263598-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER UNIVERSITY HEALTH NETWORKS (CA) 2011-10-27 — — US disclosed
WO-2011123946-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2011-10-13 — — WO disclosed
WO-2011123946-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2011-10-13 — — WO disclosed
WO-2011123947-A1 SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES UNIVERSITY HEALTH NETWORK (CA) 2011-10-13 — — WO disclosed
WO-2011123947-A1 SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES UNIVERSITY HEALTH NETWORK (CA) 2011-10-13 — — WO disclosed
US-20110009617-A1 Ruthenium Catalysts and Uses Thereof CHE CHI-MING 2011-01-13 — — US disclosed
WO-2010115279-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2010-10-14 — — WO disclosed
WO-2010115279-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME UNIVERSITY HEALTH NETWORK (CA) 2010-10-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009617-A1 Ruthenium Catalysts and Uses Thereof CYCS, POR, CPNE4 MEN1 4753/4885KMT2A 2447/4885APAF1 2105/4885
US-20260108527-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MEN1 4881/4885KMT2A 2554/4885APAF1 4661/4885
US-20240124426-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MEN1 4192/4885KMT2A 1756/4885APAF1 2758/4885
US-11858915-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 MEN1 4192/4885KMT2A 1756/4885APAF1 2758/4885
US-20110263598-A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER MAP3K6, MAP3K5, MAP3K19 MEN1 1947/4885KMT2A 780/4885APAF1 1236/4885
US-20230365537-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MEN1 4192/4885KMT2A 1756/4885APAF1 2758/4885
US-12312339-B2 Polo like kinase 4 inhibitors PLK4, PLK2, PLK3 MEN1 4192/4885KMT2A 1756/4885APAF1 2758/4885
US-20240270722-A1 POLO LIKE KINASE 4 INHIBITORS PLK4, PLK2, PLK3 MEN1 4219/4885KMT2A 1806/4885APAF1 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.